Across a landmark guideline update, a primary prevention trial, and the first treat-to-target proof of concept, the message is consistent: lower LDL for longer saves lives—and achieving that goal in practice demands goals, teams, tools, and lifestyle as the foundation.
Even with a treat-to-target protocol, only 61% of Ez-PAVE participants reached goal—but the trial's broader lesson is that combination therapy and equitable access to newer agents are the path to closing the gap.
Ez-PAVE delivers the first direct trial evidence that targeting LDL below 55 mg/dL is superior to below 70 mg/dL in ASCVD patients—providing proof of concept for treat-to-target strategies and a wake-up call about clinical inertia.
Landmark analyses from VESALIUS-CV reveal that the cardiovascular benefits of intensive LDL lowering build meaningfully over time in primary prevention—reinforcing the "lower for longer" principle and pointing toward lower LDL targets for high-risk diabetic patients.
VESALIUS-CV shows that evolocumab delivers a 31% relative risk reduction in major cardiovascular events in high-risk diabetic patients without established atherosclerosis—making a compelling case for intensive LDL lowering well before a first event.
Beyond standard risk scores, the guideline highlights key risk enhancers—including lipoprotein(a), inflammation markers, and women's health factors—and elevates coronary artery calcium scoring as a Class I tool for resolving uncertainty in primary prevention.
For the first time, the 2026 ACC/AHA guideline provides strong, evidence-based recommendations for patients who cannot tolerate statins—a group historically underserved by prior guidance. Outcome data now support bempedoic acid (from the CLEAR trial), PCSK9 monoclonal antibodies, ezetimibe, and inclisiran as viable alternatives. Rather than defaulting to high-intensity statin doses, clinicians can consider combination strategies such as a moderate-intensity statin paired with ezetimibe—a pairing shown in the RACING trial to match the cardiovascular event reduction of high-intensity monotherapy while improving tolerability and LDL goal achievement. The "rule of sixes"—where doubling a statin dose yields only an additional 6% LDL reduction versus 18% from adding ezetimibe—further reinforces early combination thinking.
The 2026 update to the ACC/AHA guideline for dyslipidemia management represents a meaningful shift in how and when clinicians should begin lipid-lowering therapy, Erin D. Michos, MD, MHS, professor of medicine, director of Women's Cardiovascular Health and associate director of Preventive Cardiology in the Division of Cardiology at Johns Hopkins University School of Medicine, explains.
This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
